High PD-L1 expression (TPS ≥ 50%) was detected in 27.3% of our cohort, which was in line with the frequency of PD-L1 overexpressing tumors (17.7%) reported by a previous study that evaluated the efficacy of ICI monotherapy in uncommon non-small cell lung cancer (NSCLC) subtypes [23]. Here, CD274 is linked to non-small cell lung carcinoma.